Alliance for Pharmacy Compounding

01/26/2026

If you run a pharmacy and want it to still exist in five years, your new favorite word is resilience. Ask Atari. Or MySpace. Or Skype.

That’s the focus of APC’s 2026 Owner Summit—helping owners build pharmacies that can handle change, stress, risk, and pricing realities without cracking.

On the agenda:
• Robert Friedman on How to Build a Fearless Brand
• Dr. Jonathan Hetterly on Beyond Burnout: The Neuroscience of Resilience in High-Performance Cultures
• Kristen Jones, RPh (Pharmacists Mutual) on Smart Insurance Strategies for Compounding Owners
• Mark D. Boesen, PharmD on The Psychology of Pricing

Bottom line: this isn’t CE fluff. It’s business survival.

And where does all business take place? On the golf course at our 3rd Annual OneFund Golf Tournament Fundraiser on March 19. ⛳

Register for Owner Summit and the golf tournament, a separately ticketed event, at https://bit.ly/3NGU3tl

01/26/2026

Last year, APC partnered with the University of Mary Washington’s Center for Business Research to survey 16,500 compounders nationwide. The result? One of the most detailed looks at pharmacy compounding in years: A Snapshot of Pharmacy Compounding in America.

With responses from every region and practice type, the Snapshot gives policymakers, patients, media, and prescribers a clear, data-backed picture of the profession.

A few fast facts:
• The median 503A pharmacy dispenses 350 compounded prescriptions a week and works with 150 prescribers
• Top therapy? Hormone replacement. #2? Veterinary meds. (Yes, GLP-1s came in #3.)
• Median staffing: 15 employees at a 503A pharmacy, 30 at an outsourcing facility
• 51% of pharmacies increased staff or hours just to keep up with GLP-1 demand

There’s a lot more inside. Bottom line: this Snapshot is a practical, shareable primer on compounding—perfect for informing people who need the facts.

👉 Download the full Snapshot and put the data to work: https://bit.ly/4jYzPHL

(Based on APC’s 2025 member survey, with support from Fagron, Medisca, and PCCA.)

01/24/2026

This opinion piece by compounding pharmacist and APC member Cheri Garvin, was published today in the Richmond Times Dispatch. It's eloquent in making a case to members of the House of Delegates for opposing the drugmaker-authored HB917, which would place duplicate, conflicting, and unneeded restrictions on compounding pharmacies in the Commonwealth.

It's paywalled, so here's a bit:

"Safety matters. I spent years helping enforce it. But safety is not improved by rules that sound tough while undermining access to legitimate care. Real safety comes from enforcing the laws we already have, targeting illegal online sellers and unlicensed operators, and allowing state boards to do the jobs they were created to do.

"Virginia does not need to reinvent pharmacy regulation to protect patients. We need to trust the system that has served them for decades and strengthen enforcement where genuine risks exist.

"If lawmakers want to address counterfeit drugs or illicit supply chains, that conversation is worth having. But that is not what this bill does. Instead, it risks cutting off care for children, for women and for patients whose needs do not fit neatly into mass production."

https://richmond.com/opinion/column/article_0c28eb67-89a5-41e5-b735-114386117b8b.html

If Virginia lawmakers want to address counterfeit drugs or illicit supply chains, that conversation is worth having, this columnist writes. But that is not what House Bill 917 does. Instead, it risks cutting off care for children, for women and for patients whose needs do not fit neatly into mass pr...

01/23/2026

Indiana lawmakers are considering a bill that would threaten access to lawful, medically necessary compounded medications that patients rely on when FDA-approved drugs don’t meet their individual needs.

If you live in Indiana, tell your lawmakers to protect Hoosier patients and oppose SB 282: https://www.votervoice.net/APC/campaigns/133039/respond

01/23/2026

Time to check out the California compounding FAQs. Feel like slogging through 85 pages of the “Enforcement and Compounding Committee Report” from the California BoP? Didn’t think so. Luckily, you can skip right to the FAQ section, which was just approved. Training, record keeping, audits — it’s all in there. If you’re in California or dispense there, you’ll probably want to check out the document … or at least the 13 (!) pages of FAQs. https://tinyurl.com/mrxb7t9c

Zyla case update. The Supreme Court is apparently interested in the case of Zyla Life Sciences v. Wells Pharma. In response to Well’s petition for the court to hear the case on appeal, the Court this week invited the US solicitor general “to file a brief in this case expressing the views of the United States.” If the court agrees to hear the case, it’s likely to become a very big and messy deal, involving states rights issues that have little to do with the original lawsuit. APC’s Scott Brunner commented on LinkedIn, the case “risks becoming about far more than a little ol’ compounded suppository.” Stay tuned.

Drug shortages in US affect quality of care, survey shows. A survey of 902 primary care clinicians shows that 87% believe drug shortages have lowered the quality of care. The survey indicates that 88% of respondents have encountered drug shortages, with endocrinologic drugs, stimulants and infectious disease medications the most affected. Clinicians say the shortages have led to increased administrative work and workplace stress. Read the full story on Medscape. https://tinyurl.com/yjpwu9vc

Thank you, Cleveland Clinic. In the midst of all the drugmaker-fueled hand wringing about pharmacy compounding, it’s good to see that the latest podcast from the Cleveland Clinic in Florida — Florida Health Care Insider — is all about “The benefits of compounded medications”.

If you missed APC’s December 2025 webinar Atrium24 — Power in Collaboration: How Atrium24 & APC Are Using Data to Protect Independent Pharmacy, with APC’s Tenille Davis — you can now check it out on Youtube. https://bit.ly/4sPALlL

01/22/2026

🎙️ Essential is live.

Tenille Davis and Matt Johnson, President & CEO of Pharma Source Direct, dig into the current—and future—state of compounded peptides, unpacking what’s changing and what pharmacies should be watching next.

We'll also break down the FDA’s revolving door, a new California law with national implications, and an emerging accreditation that could simplify life for pharmacies.

Smart, timely, and worth your time.

🎧 Listen here:
Podbean: https://bit.ly/4pJC0Qt
YouTube: https://bit.ly/3NXhwXa
Spotify: https://bit.ly/3LKRzte
Apple: https://apple.co/3LFChWU

01/21/2026

At its core, APC’s Owner Summit is about helping you run your pharmacy like the business it is—making smarter investments and getting real returns. That’s why this year’s agenda is packed with sessions focused on growth, efficiency, and ROI.

Additionally, join the separately ticketed, pre-conference workshop Super-Charge Your AI Use with Brandon Pipkin, held the day before Owner Summit begins.

⏳ Seats are limited, and registration closes soon. AI can’t register for you (yet)—so act now.

https://bit.ly/49yMRrU

01/16/2026

🚨New Rotation Student!🚨

Maria Cummins joins APC as a P4 student pharmacist at Medical University of South Carolina. She is planning in pursing a career as a community retail pharmacist with Walgreens upon graduation.

"This experience has allowed me to see how pharmacists can advocate for compounding pharmacy, work to elevate compounding practices, and help build a strong community focused on learning and sharing best practices."

Welcome to APC, Maria! 👏

01/16/2026

🚨New Rotation Student!🚨

ZaMya Williams joins APC as a P4 student pharmacist at Mercer University. ZaMya is interested in community and clinical pharmacy.

"I'm excited to complete my rotation with Alliance for Pharmacy Compounding to learn more about legislation, policies, and advocacy surrounding compounding."

She is undecided about which career path to follow post-graduation, but she is looking forward to the adventure of what is to come.

Welcome to APC, ZaMya! 👏

01/16/2026

Inaction is still action. Peptides may be tightly regulated, but that hasn’t stopped a growing “dark gray” market, as the New York Times recently reported. As APC CEO Scott Brunner notes, FDA inaction is effectively empowering that gray market—appearing more comfortable with it than allowing state-licensed pharmacies to compound peptides from high-quality, FDA-registered sources.

Older adults are dropping GLP-1s. Despite obesity affecting nearly 40% of seniors, patients 65+ are 20–30% more likely than younger patients to stop GLP-1s and less likely to restart them, according to KFF News. The reasons? Cost, GI side effects, muscle issues—and yes, cost again.

California law CE worth your time. If you dispense in or to California, WesternU’s College of Pharmacy is hosting two virtual CE courses on January 31 covering California’s non-sterile compounding law versus USP and . Speakers include a CA Board of Pharmacy supervising inspector and a pharmacy attorney—people who truly know the rules and can answer questions.

Home infusion bill moves forward. The Preserving Patient Access to Home Infusion Act (H.R. 2172) received a hearing in the House Energy & Commerce Subcommittee on Health. The bill would allow Medicare coverage for home infusion when ongoing IV therapy is needed outside a facility. APC supports the legislation, and a hearing recap is now available.

10 things not to do (Ohio edition). The Ohio Board of Pharmacy has published an 8-page PDF outlining the most common violations cited for clinics and med spas. The top offense? Purchasing from unlicensed sellers.

01/16/2026

SB 282 Update: What happened at the Jan. 14 hearing

Yesterday’s hearing demonstrated that Hoosiers know how to show up when it matters. The Senate Health Committee did not vote SB 282 forward or kill it. Instead, lawmakers hit pause after hearing extensive public testimony.
✔️ The only action taken was a technical amendment adding a $5,000 cap on civil fines
❌ No changes were made to the bill’s compounding or med spa language
🗓️ The bill will be revisited next week at the Jan. 22 committee meeting

Why the pause?
Twenty people testified — mostly Indiana pharmacists, physicians, patients, and caregivers — and the majority raised serious concerns about the bill as written, especially its impact on legitimate patient-specific compounding.

Several speakers said they could support the bill only with major revisions, urging collaboration with the Indiana Board of Pharmacy.

APC members were well represented, with six testifying about existing safeguards, USP standards, and the risk that SB 282 could unintentionally harm patient access rather than target bad actors.

Bottom line:
Jan. 14 was an information-gathering hearing, not a decision. The bill is still alive, but unresolved — and lawmakers signaled they need more time, input, and potential amendments before moving forward.

More to come after Jan. 22.

See what APC members had to say: https://bit.ly/4sGYnZw

01/15/2026

🎙️ New episode drop!

January's episode of Essential is here, and it’s one for the policy nerds (and proud of it). We’re welcoming Matt Johnson, President and CEO of Pharma Source Direct, who sits down with Tenille Davis for a smart, slightly nerdy, and genuinely fascinating deep dive into the once and future world of compounded peptides — where things stand today and where they could be headed next.

Meanwhile, our ever-curious host Andrew Kantor digs into the FDA’s revolving door, flags a new California law that could ripple across the country, and spotlights a new accreditation that might just save pharmacies a whole lot of time, stress, and headaches.

🎧 Worth a listen — trust us.



Podbean: https://bit.ly/4jRdgEQ

Youtube: https://bit.ly/49Y8F04

Spotify: https://bit.ly/4aVSlOq

Apple: https://apple.co/3Nfbkd5